Whole Genome Sequencing Analysis Software

Whole genome sequencing analysis software refers to the computational tools used to process, interpret, and report findings from WGS data. The analysis pipeline operates in two stages. Secondary analysis software handles the transformation of raw sequencing reads (FASTQ files) into variant calls: alignment, duplicate marking, base quality recalibration, and variant calling across SNVs, indels, CNVs, and structural variants. Tertiary analysis software then annotates those variants against clinical databases, filters to clinically relevant candidates, applies ACMG or AMP classification criteria, and generates the signed clinical report. At genome scale, typically 4 to 5 million raw variant calls per sample, the tertiary analysis layer is where the diagnostic work happens, and it requires purpose-built clinical software rather than research-grade tools adapted for clinical use.

The core annotation, filtering, and classification steps are similar, but WGS creates three distinct software challenges that exome analysis does not. First, data scale: a whole genome produces 4 to 5 million variant calls versus 25,000 to 40,000 for an exome, requiring multi-threaded processing and efficient database indexing to remain performant. Second, variant scope: WGS captures the full spectrum of genomic variation including non-coding variants, repeat expansions, mitochondrial variants, and structural variants that most exome capture kits miss, so the software must handle all of these in a single analysis session. Third, storage and management: WGS files are 10 to 30x larger than exome files, making enterprise data management infrastructure (variant assessment catalogs, longitudinal tracking, cohort frequency databases) a prerequisite rather than an optional add-on.

WGS supports detection and interpretation of the full spectrum of genomic variation: single nucleotide variants (SNVs), small insertions and deletions (indels), copy number variants (CNVs) including whole-chromosome aneuploidies and sub-microscopic events, structural variants (SVs) and gene fusions, repeat expansions in tandem repeat loci, mitochondrial DNA variants, and non-coding regulatory variants. This breadth is the primary clinical advantage of WGS over targeted panels and exome sequencing. Cases that remain unresolved after panel or exome testing often carry the causative variant in a region that was not sequenced or not interpretable with the smaller assay. VarSeq handles all of these variant classes within a single analysis session, without requiring separate tools for structural variants or CNVs.

Non-coding variant interpretation is one of the most challenging aspects of clinical WGS analysis. The majority of the genome is non-coding, and the functional evidence for specific non-coding variants is far less developed than for coding variants. VarSeq addresses this through CI-SpliceAI integration (a deep learning model that predicts the impact of variants on splicing, including deep intronic variants that standard consequence predictors miss), alongside regulatory region annotations, conservation scores, and literature database integration via Mastermind (Genomenon). Variants in known regulatory elements, promoter regions, and established non-coding disease loci can be flagged and prioritized. Full non-coding interpretation remains an area of active development across the field; VarSeq provides the annotation infrastructure while the clinical evidence base continues to mature.

Research-grade WGS tools are designed for exploratory analysis, where flexibility and sensitivity take priority over reproducibility and auditability. Clinical-grade software has four additional requirements. Determinism: the same input must produce identical output every run to support CLIA validation. Annotation currency: clinical databases (ClinVar, gnomAD, ClinGen) update continuously, and the software must track which database version was used for every analysis to support result traceability. Audit trail: every variant assessment, filter configuration, and classification decision must be permanently logged for CAP inspection. And quality management: software deployed in an accredited clinical laboratory should be developed under a certified QMS with controlled release processes. VarSeq is developed under an ISO 13485-certified QMS; VarSeq Dx is CE marked under IVDR 2017/746.

Yes. VSWarehouse is designed for enterprise and population-scale WGS programs, storing variant assessments, diplotype classifications, and clinical reports longitudinally across tens of thousands of genomes. For national genomic programs and health system WGS initiatives, VSWarehouse supports cohort-level allele frequency generation (building an internal population frequency database from the program's own genomes), automated reclassification monitoring when external databases update classifications of previously assessed variants, and LIMS/EHR integration for structured result delivery. VSPipeline automation handles hands-off processing from FASTQ to report for high-throughput programs where manual case initiation is not operationally viable. Deployment options include on-premises, private cloud (BYOC), and air-gapped configurations to meet the data governance requirements of population-scale programs.

VarSeq supports both short-read (Illumina) and long-read (PacBio HiFi, Oxford Nanopore) WGS data through the same tertiary analysis framework. Long-read sequencing resolves regions that are systematically difficult for short-read platforms: complex structural variants, tandem repeats, segmental duplications, and highly homologous gene families like SMN1/SMN2 and CYP2D6. Sentieon supports long-read alignment and variant calling, with output feeding directly into VarSeq for annotation and clinical interpretation. For programs where short-read WGS leaves a diagnostic gap, particularly in rare disease cases with negative short-read results, long-read WGS with the same downstream interpretation platform eliminates the need to rebuild the analysis workflow for the new assay type.